Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Phenome-Wide Analysis of Short- and Long-Run Disease Incidence Following Recurrent Pregnancy Loss Using Data From a 39-Year Period

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With ST-Segment-Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Early Systolic Lengthening in Patients With ST-Segment-Elevation Myocardial Infarction: A Novel Predictor of Cardiovascular Events

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Neonatal Risk in Children of Women With Congenital Heart Disease: A Cohort Study With Focus on Socioeconomic Status

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of Ischemic Stroke in Individuals With and Without Aortic Valve Stenosis: A Danish Retrospective Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real-life patient experience, including bleeding risk, are lacking. Our objective was to compare major bleeding events and nonpersistence between the nonvitamin K antagonist oral anticoagulant apixaban and other nonvitamin K antagonist oral anticoagulants (dabigatran and rivaroxaban) and warfarin in a contemporary, nation-wide cohort of patients with nonvalvular atrial fibrillation.

METHODS AND RESULTS: Of 54 321 patients (median age, 73 years; 56% male; mean CHA2DS2-VASc score, 2.9), 7963, 6715, 15 413, and 24 230 patients initiated apixaban, rivaroxaban, dabigatran, and warfarin, respectively. Apixaban and rivaroxaban initiators were older, less often male, with higher HAS-BLED and CHA2DS2-VASc scores compared with dabigatran and warfarin initiators. A total of 2418 patients (4.5%) experienced a major bleeding event over all available follow-up. In this period, rivaroxaban (hazard ratio [HR] [95% CI], 1.49 [1.27-1.77]), dabigatran (HR, 1.17 [1.00-1.38]), and warfarin (HR, 1.23 [1.05-1.43]) users were significantly more likely to bleed than apixaban users. Findings were similar when restricted to the first 30 days after OAC initiation. Risk of nonpersistence was higher for dabigatran (HR, 1.45 [1.33-1.59]) and warfarin initiators (HR, 1.22 [1.12-1.33]), but not for rivaroxaban initiators (HR, 1.07 [0.96-1.20]) compared with apixaban initiators.

CONCLUSIONS: In a real-world cohort of nonvalvular atrial fibrillation patients, apixaban had a lower adjusted major bleeding risk compared with rivaroxaban, dabigatran, and warfarin. Apixaban had a lower risk of nonpersistence compared with dabigatran and warfarin and similar risk compared with rivaroxaban.

Original languageEnglish
JournalJournal of the American Heart Association
Volume6
Issue number2
Pages (from-to)e004517
ISSN2047-9980
DOIs
Publication statusPublished - 14 Feb 2017

    Research areas

  • Journal Article

ID: 50128089